Aro Biotherapeatics


Isogenica Ltd, a leader in the use of synthetic biology and in vitro display for the discovery and optimisation of novel biotherapeutics, today announced an expansion of the collaboration and license agreement signed with Aro Biotherapeutics in June 2018.


Under the expanded agreement, Isogenica will use its CIS Display platform to help Aro achieve its goal of developing novel CentyrinsTM against multiple targets for cell - specific delivery.  The rapid screening via CIS display of multiple large libraries with different antigen binding surfaces has already enabled discovery of high affinity Centyrins TM that bind to a diversity of unique epitopes on target proteins, and that do not require affinity maturation.


Dr Adam Collier, Isogenica’s Director of Business Development commented: “it is very satisfying to see that the success of the first six months of this collaboration has resulted in this strengthening of the relationship. We look forward to continuing to work with the team at Aro in the search for novel Centyrins TM with high therapeutic potential in oncology and immunology”.


Isogenica is developing LlamdA™ (single domain VHH) and Alexandria™ (human Fab) therapeutic antibodies from its proprietary fully synthetic antibody libraries and leveraging its CIS Display and Colibra™ technologies to accelerate the discovery and development process.  Over the last four years Isogenica has entered into eight significant partnerships, leveraging its libraries, technologies and expertise to build a broad pipeline of programs that are now advancing into pre-clinical and early clinical development with our partners.


For more information, visit



Adam Collier, Director of Business Development

T: 01799 533 680

E: This email address is being protected from spambots. You need JavaScript enabled to view it.